Exhibit 99.2

BIOSPECIFICS TECHNOLOGIES CORP.
Consolidated Statements of Operations
(unaudited)

	Three Months Ended September 30,						Nine Months Ended September 30,
		2009			2008			2009			2008
Revenues:
Net Sales	$	19,089		$	13,042		$	36,194		$	29,841
Royalties		481,197			-			856,597			2,028
Licensing fees		266,282			266,281			1,298,844			798,844
Consulting fees		70,000			70,000			210,000			354,185
Total Revenues		836,568			349,323			2,401,635			1,184,898
Costs and expenses:
Research and development		112,920			71,737			352,983			260,440
General and administrative		1,176,885			866,574			3,484,341			2,840,346
Total Cost and Expenses		1,289,805			938,311			3,837,324			3,100,786
Operating Loss		(453,237	)		(588,988	)		(1,435,689	)		(1,915,888	)
Other income (expense):
Interest income		24,140			31,511			28,685			89,314
Interest expense		-			46,979			(39	)		46,528
Other, net		600			104,203			(8,863	)		108,730
		24,740			182,693			19,783			244,572
Loss before benefit for income tax		(428,497	)		(406,295	)		(1,415,906	)		(1,671,316	)
Income tax benefit		46,376			192,287			-			192,287
Net loss	$	(382,121	)	$	(214,008	)	$	(1,415,906	)	$	(1,479,029	)
Basic and diluted net loss per share	$	(0.06	)	$	(0.04	)	$	(0.23	)	$	(0.25	)
Shares used in computation of basic and diluted net loss per share		6,075,758			5,976,937			6,034,301			5,803,497

BIOSPECIFICS TECHNOLOGIES CORP.
Selected Consolidated Balance Sheet Data
(unaudited)

	September 30, 2009		December 31, 2008
Cash and cash equivalents	$	4,267,591	$	3,494,150
Short-term investments		5,022,854		900,000
Accounts and income tax receivable		1,482,616		6,952,781
Working capital		9,157,129		9,422,245
Total assets		12,337,717		12,831,361
Long-term liabilities		4,321,154		4,660,427
Total stockholders' equity		6,394,870		6,178,539